These studies suggest that ATM mutations can be the potential marker for predicting the clinical outcome and response to immune checkpoint blockade in endometrial cancer, but the intrinsic mechanism of ATM mutation and antitumor immune activation should be better described. The gene discussed is ATM; the disease is endometrial cancer.